Please use this identifier to cite or link to this item:
http://repository.tma.uz/xmlui/handle/1/5892
Title: | Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis |
Authors: | Мukhammadievа S.М., Nabievа D.A., Abduazizova N.X., Xidoyatova M.R. |
Keywords: | ankylosing spondylitis, diagnosis, treatment, TNF-α inhibitors, infliximab. |
Issue Date: | Dec-2022 |
Publisher: | Switzerland |
Abstract: | This article is devoted to the effectiveness of the treatment of ankylosing spondylitis (AS), one of the chronic inflammatory disease of the musculoskeletal system. The study included 53 patients with active AS (BASDAI activity index >4) and failure of standard therapy, which included the TNF-a inhibitor infliximab (INF) at a dose of 3-5 mg/kg intravenously for 0, 2, 6 weeks and next every 8 weeks. In patients treated with INF, a positive clinical effect was achieved by indicators BASDAI and BASMI scores, as well as a remarkable positive result in dynamics vertebral mobility index and BASFI score. Tolerability of INF patients was satisfactory. |
URI: | http://repository.tma.uz/xmlui/handle/1/5892 |
ISSN: | 2729-8043 |
Appears in Collections: | Thesis, Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1. Мухаммадиева С.М. з.pdf | Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis | 395.6 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.